Mark Rosenblum

Mark Rosenblum is the current Managing Director of New Ventures at Redesign Health. Prior to joining Redesign Health, Mark served as Vice President of Healthcare Services Equity Research at Morgan Stanley from April 2015 to September 2018. Mark was part of Institutional Investor #2 ranked team covering PBMs, drug retailers, labs, CROs, CMOs, healthcare technology, and drug distribution. From August 2013 to March 2015, Mark was an Investment Banking Associate with Jefferies LLC's Global Healthcare Group where they provided advisory services to corporations and private equity funds on M&A, strategy, and capital raising. Mark also served as a Research Analyst and Vice President at Epoch Investment Partners from October 2018 to January 2020. Epoch Investment Partners is a global investment manager with $35B in AUM. In their role at Epoch, Mark worked as an equity analyst covering healthcare and communication services. Prior to their role as a Research Analyst, Mark served as a Senior Associate in Portfolio Management at Epoch from February 2009 to July 2011.

Mark Rosenblum has an MBA from Duke University's Fuqua School of Business and a Bachelor of Science in finance from the University of Maryland.

Mark Rosenblum reports to Brett Shaheen, CEO. Some direct reports include Kyle Tatz - Head of New Ventures, Courtney Parr - New Ventures Associate. They are on a team with Yunus S. - VP, Machine Learning, Parker Hayden - Head of X Ventures, and Max Pomeranc - Head of Public Policy.